Nitric oxide-dependent neovascularization role in the lower extremity disease

Current Pharmaceutical Design

Volumn 13, Issue 35, 2007, Pages 3591-3596

  Arellano Mendoza, Mónica G ^a   Robles, Hilda Vargas ^b   Romo, Eunice ^b   Rios, Amelia ^b   Escalante, Bruno ^b  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Angiogenesis; Arteriogenesis; Nitric oxide; Peripheral arterial disease; Revasculatization

Indexed keywords

ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PLASMID DNA;

ANGIOGENESIS; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CATABOLISM; CELL MIGRATION; DIET SUPPLEMENTATION; DRUG TARGETING; EPIDEMIOLOGICAL DATA; EXTRACELLULAR MATRIX; GENE THERAPY; HINDLIMB; HUMAN; INTERMITTENT CLAUDICATION; LEG BLOOD FLOW; LEG DISEASE; LEG ISCHEMIA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; UNITED STATES;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ARTERIAL OCCLUSIVE DISEASES; ENDOTHELIAL CELLS; GENE THERAPY; HUMANS; ISCHEMIA; LOWER EXTREMITY; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PERIPHERAL VASCULAR DISEASES; PREVALENCE; RISK FACTORS; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

EID: 36949008535     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207782794103     Document Type: Review

References (61)

1. McDermott M. The magnitude of the problem of peripheral arterial disease: Epidemiology and clinical significance. Cleveland Clin J Med 2006; 73: S2-7.
2. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional radiology, and the ACC/AHA task force on practice guidelines. Circulation 2006; 113: e463-654.
3. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, et al. Ankle-arm index as a marker of atherosclerosis in the cardiovascular Health Study. Circulation 1993; 88: 837-45.
4. Yusuf S, Sleight P, Pogue J, Bosch, Davies R, Dagenais G, et al. Effects of an angiogenesis-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart outcomes Prevention Evaluation Study Investagators. N Engl J Med 2000; 342:145-53
5. Powell JT, Edwards RJ, Worrell PC, Franks PJ, Greenhalgh RM, Poulter NR. Risk factors associated with the development orf peripheral arterial disease in smokers: a case-control study. Atherosclerosis 1997;129: 41-8.
6. Donohoe ME, Fletoon JA, Hook A, Powel R, Robinson I, Stead JW, et al. Improving foot care for people with diabetes mellitus: a randomized controlled trial of an integrated care approach. Diab Med 2000; 17: 581-7.
7. Olin JW. Current concepts; thromboangiitis obliterants (Buerger's disease). N Engl J Med; 343: 864-9.
8. Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease: implications for the mechanism of the training response. Circulation 1994; 90: 1866-74.
9. Regensteiner JG, Meyer TJ, Krupski WC, Cranford LS, Hiat WR. Hospital vs. home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology 1997; 48: 291-300.
10. Lundgren F, Dahllof AG, Schersten T, Bylundfellenius AC. Muscle enzyme adaptation in patients with peripheral arterial insufficiency-spontaneous adaptation, effect of different treatments and consequences on walking performance. Clin Sci 1989; 77: 485-93.
11. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty factors influencing long-term success. Circulation1991; 83(suppl): 70-80.
12. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 553-60.
13. Waters RE, Teijung RL, Peters KG, Annex BH. Preclinical models of human peripheral arterial occlusive disease: Implications for investigation of therapeutic agents. J Appl Physiol 2004; 97: 773-80.
14. Pu LQ, Jackson S, Lachapelle KJ, Arekat Z, Graham AM, Lisbona R, et al. A persistent hindlimb ischemia model in the rabbit. J Invest Surg 1994; 7: 49-60.
15. Westerweel PE, Rookmaaker MB, vanZonneveld AJ, Bleys RLAW, Rabelink TJ, Verhaar MC. A study of neovascularization in the rat ischemic hindlimb using araldite casting and spalteholtz tissue clearing. Cardiovasc Pathol 2005; 14:294-7.
16. Schiekofer S, Galasso G, Sato K, Kraus BJ, Walsh K. Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network. Arterioscler Thromb Vasc Biol 2005; 25: 1603-9.
17. Luque Contreras D, Vargas Robles H,Romo E, Rios A, Escalante B. The role of nitric oxide in the post-ischemic revascularization process. Pharm Ther 2006;112: 553-63
18. Baffour R, Berman J, Garb JL, Rhee SW, Kaufman J, Friedmann P. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in the rabbit model of acute lower limb ischemia: dose response effect of basic fibroblast growth factor. J Vasc Surg 1992; 16: 181-91.
19. Takeshita S, Pu LQ, Stern LA, Sniderman AD, Bunting S, Ferrara N, et al. Intramuscular administration of vascular endothelial growth factor induces dose dependent collateral artery augmentation in rabbit model of chronic limb ischemia. Circulation 1994; 90: 228-34.
20. Yang HT, Deschenes MR, Ogilvie RW, Terjung RL. Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation. Cir Res 1996; 79: 62-9.
21. Luque Contreras D, Jimenez Estrada I, Martinez-Fong D, Segura B, Guadarrama JC, Paniagua Sierra R, et al. Hindlimb claudication reflects impaired nitric oxide-dependent revascularization after ischemia. Vasc Pharmacol 2007; 46: 10-5.
22. D'Andrea LD, DelGatto, Pedone C, Benedetti E. Peptide-based molecules in angiogenesis. Chem Biol Drug Des 2006. 67: 115-26,
23. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia role of the HIF system. Nat Med 2003; 9: 677-84.
24. Ziche M, Morbidelli L, Choudhruri R, Zhang HT, Donnini S, Granger HJ, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997; 99: 2625-34.
25. Dvorak HF, Flier J, Frank H. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-9.
26. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis; a moving target for therapeutic intervention. J Clin Invest 1999; 103: 1237-41.
27. Varner JA, Brooks PC, Cheresh DA. The integrin αvβ3: angiogenesis and apoptosis. Cell Adhesion Communication 1995; 3: 367-74.
28. Hirschi KK, Damore PA. Pericytes in the microvasculature. Cardiovasc Res 1996;32: 687-98.
29. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Med 2000; 6: 389-95.
30. vanRoyen N, Piek JJ, Bushmannn I, Hoefer I, Vosuil M, Schaper W. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res 2001; 49: 543-53.
31. Vallance P, Collier J, Moncada S. Effects of endothelium derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 997-1000.
32. Cho A, Mitchel L, Koopmans D, Langille BL. Effects of changes in blood flow rate on cell death and cell proliferation in carotid arteries of immature rabbits. Circ Res 1997; 81: 328-37.
33. Herzog S, Sager H, Khmelevski E, Deylig A, Ito WD. Collateral arteries grow from preexisting anastomoses in the rat hindlimb. Am J Physiol Heart Circ Physiol 2002; 283: H2012-20.
34. Labrador V, Chen KD, Li YS, Muller S, Stoltz JF, Chien S. Interactions of mechanotransduction pathways. Biorheology 2003; 40: 47-2.
35. Resnick N, Yahar H, Khachigian LM, Collins T, Anderson KR, Dewey PC, et al. Endothelial gene regulation by laminar shear stress. Anal Quant Cardiol Adv Exp Med Biol 1997; 430: 155-64.
36. Palmer-Kazen U, Wahlberg E. Arteriogenesis in peripheral arterial disease. Endothelium J Endothel Cell Res 2003; 10: 225-32.
37. Schaper W, Ito WD. Molecular mechanisms of coronary collateral vessel growth. Cir Res 1996; 79: 911-9.
38. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
39. Amano K, Matsubara H, Iba O, Okigaki M, Fujiyama S, Imada T, et al. Enhancement of ischemia-induced angiogenesis by eNOS overexpression. Hypertension 2003; 41: 156-62.
40. Silvestre JS, Tamarat R, Senbonmatsu T, Icchiki T, Ebrahimian T, Iglarz M, et al. Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ Res 2002; 90: 1072-9.
41. Prior BM, Lloyd PG, Ren J, Li Z, Yang HT, Laughlin MH, et al. Arteriogenesis: role of nitric oxide. Endothelium J Endothel Cell Res 2003; 10: 207-16.
42. Unthank JL, Nixon JC, Lash JM. Early adaptations in collateral and microvascular resistances after ligation of the rat femoral artery. J Appl Physiol 1995; 79: 73-82.
43. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101: 2567-78.
44. Yu J, deMuinck ED, Zhuang Z, Drinane M, Kauser K, Rubanyl GM, et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Nat Acad Sci USA 2005; 102: 10999-1004.
45. Smith RS, Lin KF, Agata J, Chao L, Chao J. Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. Arterioscler Thromb Vasc Biol 2002; 22: 1279-85.
46. Namba T, Koike H, Murakami Y, Aoki M, Makino H, Hashiya N, et al. Angiogonesis induced by endothelial growth factor expression in a rat hindlimb ischemia model. Circulation 2003; 108: 2250-7.
47. Hudlicka O, Brown M, Egginton S. Angiogenesis in skeletal and cardiac muscle. Physiol Rev 1992; 72: 369-417.
48. Dulak J, Jozkowicz A, Dembinska-Kiec A, Guevara I, Zdzienika A, Znoddsinska-Grochot D, et al. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20: 659-66.
49. Noiri E, Lee E, testa J, Quigley J, Colflesh D, Keese CR, et al. Podokinesis in endothelial cell migration: role of nitric oxide: Am J Physiol Cell Physiol 1998; 274: C236-44.
50. Beauvais F, Miehel -L, Dubertret L. Exogenous nitric oxide elicits chemotaxis of neutrophils in vitro. J Cell Physiol 1995; 165: 610-4.
51. Murohara T, Witzenhichler B, Syridoulos I, Asahara T, Ding B, Sullivan A, et al. Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler Thromb Vasc Biol 1999; 19: 1156-61.
52. Rossig L, Fichtlscherer B, Breitshopf K, haendeler J, Zeiber AM, Mulsch A, et al. Nitric oxide inhibits caspase-3 by s-nitrosation in vivo. J Biol Chem 1999; 274: 6823-6.
53. Hood JD, Meininger CJ, Ziche M, Ganger HJ. VEGF up-regulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 274: H1054-8.
54. Tamarat R, Silvestre JS, Kubig N, Benessiano J, Durietz M, deGasparo M, et al. Endothelial nitric oxide synthase lies downstream from angiotensin II-induced angiogenesis in ischemic hindlimb. Hypertension 2002; 39: 830-5.
55. Parenti A., Morbidelli L, Ledda F, Granger HJ, Ziche M. The bradykinin/ B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide pathway. FASEB J 2001; 15: 1487-9.
56. Boger RH, Bode-Boger SE, Thiele W, Creutzing A, Alexander K, Frolich JC. Restoring vascular nitric oxide formation by L-Arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998; 32: 1336-41.
57. Urbich C, Heeschen C, Aicher A, Dembach E, Zeiher AM, Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003; 108: 2511-6.
58. Tarzami ST, Sing JP. Pharmacological revascularization in coronary and peripheral vascular disease. Expert Opin Invest Drugs 2004; 13: 1319-26.
59. Martinez-Gonzalez J, Badimon L. Influence of statin use on endothelial function: from bench to clinics. Curr Pharm Des 2007; 13(17):1771-86.
60. Miura S, Saku K. Regulation of angiogenesis and angiogenic factors by cardiovascular medications. Curr Pharm Des 2007; 13(20): 2113-7.
61. Tarr JM, Eggleton P, Winyard PG. Nitric oxide and the regulation of apoptosis in tumour cells. Curr Pharm Des 2006; 12(34): 4445-68.